{
  "docId": "019de071-f36b-702d-acba-b009d415a6aa",
  "docSlug": "7f10ea97b4031d406788e9f98a2cb8e4",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 36 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 36,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f36b-702d-acba-b009d415a6aa/31",
  "deckHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa",
  "deckJsonHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa.json",
  "deckAnchorHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "ALKS 1140 clinical development program includes early evaluation of prosynaptic mechanism of action; First-in-human (FIH), single-ascending dose study underway; Phase 0 biomarker research underway and intended to inform indication priorities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2d3829c-f746-4b82-84a8-1e8166a5a7f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.49,
        "x": 0.46,
        "y": 0.3
      },
      "kind": "list",
      "text": "Assess target engagement: histone acetylation in PBMCs; Assess PD response: Synaptic proteins in blood and CSF, Synaptic density and structure in brain (SV2A PET, MRI), Functional synaptic biomarkers (qEEG)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffacdaec-3e3c-40c6-8571-6546a7ef6d32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.49,
        "x": 0.46,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Characterize synaptopathy in patients using fluid, neuroimaging and electrophysiological biomarkers to prioritize indications based on robust, measurable changes in synaptic integrity, density and function",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce21fbfb-b48c-4d42-9eda-8392dc0ab35b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "PBMCs: Peripheral blood mononuclear cells; CSF: Cerebrospinal fluid; PET: Positron emission tomography; qEEG: Quantitative electroencephalogram",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a49ac56f-013b-4791-8be3-ffbab2f0af78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.49,
        "x": 0.46,
        "y": 0.21
      },
      "kind": "subtitle",
      "text": "Phase 1 Biomarkers Assess Target Engagement and Pharmacodynamic (PD) Response",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "151cb06c-ce1d-452d-94ee-2b8e7cabc555",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.49,
        "x": 0.46,
        "y": 0.66
      },
      "kind": "subtitle",
      "text": "Phase 0 Biomarker Research Objective",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a70552ba-0732-4627-8a27-6930bc924d51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 1140: First-in-Human Study Underway and Clinical Strategy Focused on Early Validation of Biology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8e88c4b-dbb7-4d56-830c-aa2d90f60ca7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "6d6e3bd6-dd27-48ac-909d-ecf02cb76c9b",
      "evidence": "The slide contains a list of bullet points describing the ALKS 1140 clinical development program.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e1affb3-fc2c-436d-a5c0-492bd8d09819",
      "evidence": "The deck presents an overview of the innovation pipeline and its potential benefits",
      "position": 0,
      "objective": "Highlighting the importance of Alkermes' innovation pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}